No detectable increased risk of birth defects following maternal IV administration of ondansetron
Researchers from the Brigham and Women’s Hospital in Boston (MA) and the Harvard T.H. Chan School of Public Health have published an update to their 2018 study (see here). The authors state that this update was provided to specifically address the findings of another study published in early 2019 (see here) which suggested an association between the clinical administration of IV ondansetron in the first trimester and increased risks of some specific birth defects (incl. cardiovascular anomalies and orofacial clefts). More information about this update can be found here.